Influence of biflorin on the labelling of red blood cells, plasma protein, cell protein, and lymphocytes with technetium-99m: in vitro study

In this paper we report the results of an in vitro study involving the influence of biflorin (an o-quinone isolated from Capraria biflora L. that has potent antimicrobial activity) on the Tc-99m labeling of red blood cells, plasma protein, cells protein, and lymphocytes. Blood was withdrawn from Wistar rats and incubated with various concentrations of biflorin, and solutions of stannous chloride and Tc-99m were added. Plasma (P) and red blood cells (RBC) were isolated, precipitated, and centrifuged, and soluble (SF) and insoluble (IF) fractions were isolated. The results show that the highest concentration (100 percent) of biflorin is able to reduce the uptake of Tc-99m ( percentATI) on RBC and the fixation on IF-P. To study the influence of biflorin on 99mTc lymphocyte labeling, human blood was submitted to a technique with Ficoll-Hypac and centrifuged, and white cells were isolated. Lymphocytes (2.5 mL; 1.0 x 10(6) cells/mL) were obtained and a 0.2 mL solution was incubated with biflorin (0.1 mL). Solutions of stannous chloride and 99mTc were added. Lymphocytes were separated and the percentATI bound in these cells was evaluated. A reduction in percentATI (from 97.85 ± 0.99 to 88.86 ± 5) was observed for RBC and for IF-P (73.24 ± 5.51 to 20.72 ± 6.95). In this case the results showed no decrease in percentATI for the lymphocytes with biflorin.

Neste artigo relatam-se os resultados de um estudo in vitro envolvendo a influência da biflorina (uma o-quinona isolada de Capraria biflora L. que possui uma potente atividade antimicrobiana) na marcação do Tc-99m em células vermelhas do sangue, proteínas do plasma, proteínas celulares e em linfócitos. O sangue foi coletado de ratos Wistar e incubado com várias concentrações de biflorina, e soluções de cloreto estanoso (SnCl2) adicionando-se Tc-99m. O plasma (P) e as células vermelhas do sangue (CVS) foram isolados, precipitados e centrifugados, isolando-se as frações solúveis (FS) e insolúveis (FI). A maior concentração de biflorina (100 por cento) é capaz de reduzir a captação do Tc-99m ( por centoATI) nas CVS e a fixação na FI-P. Uma solução de 0,2 mL de linfócitos (2,5 mL; 1.0 x 10(6) células/mL), obtidos por centrifugação de sangue humano tratado com Ficoll-Hypac, foi incubada com biflorina (0,1 mL). Soluções de cloreto estanoso e Tc-99m foram então adicionadas. Os linfócitos foram separados e o por centoATI presente nessas células foi avaliado. Uma redução no por centoATI (de 97,85 ± 0,99 a 88,86 ± 5) foi observada para CVS e para FI-P (73,24 ± 5,51 a 20,72 ± 6,95). Os resultados não mostraram decréscimo no por centoATI para os linfócitos com biflorina.

Evaluation of the effect of mitomycin-C on the bioavailability of technetium-99m-labelled sodium pyrophosphate in mice.

We have reported that drugs alter the biodistribution of radiopharmaceuticals used in diagnostic imaging in nuclear medicine. Knowledge of such altered biodistribution is important in making diagnostic from scintigraphy. Mitomycin-C is used as component of many chemotherapeutic regimens to treat different tumors. The biological activities of mitomycin-C can be explained by its ability to inhibit deoxyribonucleic acid synthesis. Since patients on chemotherapeutic treatment can be submitted to nuclear medicine procedures, we studied the mitomycin-C effect on the bioavailability of the technetium-99m-labelled sodium pyrophosphate (9mTc-PYP) using an animal model. Mitomycin (0.45 mg) was administered by ocular plexus way Balb/c mice. One hour after the last dose, 99mTc-PYP (7.4 MBq) was administered and after 0.5 hr the animals (n = 15) were rapidly sacrificed. The organs were isolated, the radioactivity counted in a well counter and the percentage of radioactivity (%ATI) calculated. The results have shown that in the treated animals the %ATI has been decreased in spleen, thymus, heart and brain and increased in lung, liver and bone. The effect of this chemotherapeutic drug on the 99mTc-PYP biodistribution was statistically significant (Wilcoxon test, p < 0.05) and it could be explained by the metabolization or therapeutic action of mitomycin-C.